Drug news

Nice rejectes Esbriet (InterMune) as a treatment for Pulmonary Fibrosis

Read time: 1 mins

Last updated:30th Nov 2012

Published:30th Nov 2012

Source: Pharmawand

The National Institute for Health and Clinical Excellence (NICE) has rejected the use of Esbriet(pirfenidone), from InterMune, on the National Health Service to treat patients with idiopathic Pulmonary Fibrosis as it finds the drug is not cost effective.

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Click here to view

Related news and insights

Drug news

Completion of enrollment in phase III Orbit and Cosmic studies evaluating setrusumab (UX 143) for the treatment of osteogenesis imperfecta (OI)

Ultragenyx Pharmaceutical Inc. announced that all patients have been enrolled across the Phase III Orbit and Cosmic studies evaluating setrusumab (UX 143) in pediatric and young adult patients with osteogenesis imperfecta (OI)

1 mins

Drug news

FDA approves trastuzumab-strf for HER2-overexpressing breast and gastric/GEJ cancer

The FDA has approved trastuzumab-strf (HLX02; Hercessi), a trastuzumab (Herceptin) biosimilar as adjuvant therapy for patients with HER2-overexpressing breast cancer, and as treatment for patients with HER2-overexpressing metastatic breast cancer, and HER2-overexpressing metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma

2 min

Drug news

Safety of switching from a Vitamin K antagonist to a non–Vitamin K antagonist oral anticoagulant in frail older patients with atrial fibrillation.

FRAIL-AF trial investigators set out to study the question of whether frail, elderly patients with atrial fibrillation who were doing well with vitamin K antagonists (VKA) should be switched to direct-acting oral anticoagulants (DOAC).

1 min

See all news